Knowledge Center
Article / Oct 01, 2012
New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit
Source:
Drug Development and Delivery, October 2012
鈥淎n issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as 四色AV, that can apply multiple platforms, to increase the probability of solving the聽 problem, and deliver the desired outcome.鈥
Related links
Also in the Knowledge Center
/ Apr 20, 2017
Method of production of inhalable composite particles using a three-fluid nozzle
Read more
Scientific Article
/ Dec 07, 2016
Impact of Spray Drying on Superoxide Dismutase Activity in Composite Systems with Optimal Aerodynamic Performance for Dry Powder Inhalers
Read more
Scientific Article
/ Dec 07, 2016
Optimization of Supercritical CO2 Assisted Spray Drying for the Production of Inhalable Composite Particles
Read more
Scientific Article